Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
8th grade Avg
|
New words:
AAD, AAV, AB, Abdullah, AbioMed, abreast, abstract, abundant, ADC, Advantix, affinity, agalsidase, ago, AIS, alfa, alglucosidase, Allegra®to, allele, alleviate, Allston, Anagni, analogApidra®advanced, andEcole, andNet, angiogenic, Ankara, APA, apoB, Arabia, aseptic, ASO, aspect, assumption, asterisk, Astra, atherogenic, Aubagio, Auckland, Audion, austerity, Aviesan, backlog, BALO, Bangladesh, banker, bargain, baseline, bendamustine, biennial, Big, binder, bio, biomarker, biomedicine, bioreactor, biosafety, biosurgery, bluetongue, Boehringer, bowel, BPCIA, branch, Brazilia, bribery, broken, Broward, BTV, buffered, bursal, CAA, Campath, Canal, Carac, cardiac, Carticel, CAVD, CCI, CDC, Celsior, Centerview, centric, Certifect, certiori, Ceva, chairmen, chapter, Cholestagel, Chondrocyte, CHSCT, Cipla, circumvented, CKD, cliff, clofarabine, Clolar, Clorafabine, clostridial, CMC, coherent, Compact, Concommitantly, configuration, continent, Coophavet, Copenhagen, corridor, credibility, CSR, CV, Darmouth, Database, debilitating, decree, deed, deferral, deleverage, depository, Dermik, destined, destruction, dialog, dietetary, differencesattributable, Diffuse, digestive, disaster, disgorgement, disruption, DLBCL, donepezil, drew, DVI, dysregulated, edaravone, EDL, Elaxotine, eliglustat, elucidating, emotional, encounter, encountered, Entertainment, envelope, EPA, Epicel, eroded, escrow, ESMO, esthetic, Evoltra, EWC, exchangeand, exchangein, experimental, Fabry, fake, FASB, fatal, FCPA, FH, flagged, Floor, Fludara, Focal, follicular, footprint, foreclosed, fowl, Framingham, Franciso, fraudulently, freedom, FrenchDocument, Fresolumimab, fromEcole, fromOperating, Gainesville, Gastrointestinal, Gaucher, GAVI, GCVRZ, GDUFA, Geel, Gerland, globe, Goiter, GPEC, GPL, Grampositive, grantor, GRC, Greek, Greylock, grower, Harvard, Haverhill, headcount, Hectorol, HeFH, hematopoeitic, henceforth, hired, HMA, Hodgkin, HoFH, Horsham, humanitarian, Hyalgan, Hyaluronic, hylan, hyperphosphatemia, IAA, IBD, ILO, imiglucerase, Immunosuppression, IMOJEVTM, impeachment, implicate, implicit, implied, inCurrency, inFabrazyme, Ingelheim, inquiring, integrin, Interestingly, intravenously, IP, iPhone, IPPOX, itemfair, itemOther, itemsFair, ivermectin, IVI, ix, JAKARTA, Johnson, Jonexa, JPML, JPO, Labour, Lacoste, Landgericht, layoff, Lee, LemtradaTM, lengthy, Lentilly, Leukine, liabilitiesandOther, liabilitiesline, lice, lifelong, lipopenic, litigationare, litigationin, losartan, lotion, LPA, LSD, Ltda, Lumizyme, Lumizyme®are, Lymphoblastic, lysosomal, MA, MAA, MACI, magnitude, Manhattan, mantle, Marek, markedly, McKinsey, MCO, meaningfully, meningitidisbacteria, meter, Mine, mipomersen, mislabeled, Monsanto, Montevideo, Mozobil, Multidistrict, multikinase, municipal, Myozyme, Myozyme®and, Nanchang, Nanjing, Nanyang, native, navigate, NEJM, NHI, NHL, nonaction, Northborough, Noventa, Obama, ofCerezyme, ofFondation, ofGenzyme, ofSynvisc, OGD, oligonucleotide, orderly, outlook, outset, ovary, panel, Parkinson, Paulinia, perspective, Perth, PetArmor, phosphate, PIGF, pillar, Pirbright, placental, PlGF, POC, pocket, Pompe, possession, PPACA, PPD, prepaid, Prevelle, Previcox, Priest, privacy, procurement, pronounced, pursuit, quanta, Raleigh, rationale, Rebif, rebounded, reconversion, recourse, Red, redacted, redesigned, reevaluation, refocused, relieving, Renagel, Renvela, replicating, requisite, restraining, rhASM, Riceland, Ridgefield, Rifa, Rim, rituxan, rituximab, ROA, Rock, ruminant, Sabin, SAD, Saglik, Sanofiexcluding, sarcopenia, Sarilumab, Saudi, Sawai, Schneider, SCIL, Seikagaku, Seiyaku, seminar, Seprafilm, sevelamer, Shire, sight, Singapour, skill, skip, Sklice, slight, solve, sovereign, sparked, speed, spike, stand, standpoint, Stifung, stomach, Stripping, sublicensee, subordinated, subsidized, Substrate, Suffolk, suicidality, summer, Super, synvisc, systolic, TAFI, Takada, talented, tangible, TangShan, Teijin, tertiary, TGF, theBALOby, theFair, thirteenth, Thymoglobulin, Thymoglobuline, Thyrogen, ticker, tighter, till, timeframe, Topaz, touched, Transatlantic, Transpac, TRV, TSR, ULMWH, unapproved, unbiased, unbranded, unclear, unconstitutional, undefined, understood, unemployment, uninvested, unpredictable, unproved, unregulated, unvested, Urunleri, USD, Valeant, vanilloid, Vaxxitex, Velcera, Vetoquinol, vigilance, viii, Virbac, visceral, viscosupplementation, Vita, warehouse, Warp, Waterford, wellbeing, whichever, Whilst, widened, workplan, Zaltrap, Zeneca, Zimmer, Zimulti
Removed:
Abrika, ACIP, adjudication, administratively, admitted, Agreal, Agricole, Alaska, Alba, Albany, allocating, Anchen, Andrx, answer, anticoagulant, antihypertensive, Arava, Armour, Army, artesunate, ascontinu, auction, benchmark, BfArM, biggest, bilateral, Bioenergy, biology, bivalent, Bruel, Bulgarian, caption, check, checked, Chicago, ChimeriVax, Citigroup, claimsinter, clarify, cleared, closure, Connaught, conspiring, constantly, contact, contested, continu, continuity, counter, counteracting, CP, decoy, Delaware, delisting, deny, deployed, depressive, designate, discontinue, Dyax, dynamism, enjoined, entreprise, EPS, Eurolist, experiencing, fixing, flu, formulate, freshmen, gathering, gave, GEICAM, gemcitabine, Genfit, Glow, Golden, Guangdong, hear, hereinafter, Hospira, Iboxx, Idaho, IDflu, ilepatril, imojev, Impax, improper, inCumulative, inevitably, infected, inhibit, input, Inspector, intanza, interbank, interrupt, intervene, interview, intradermal, jour, judge, judged, Kentucky, larotaxel, Laval, lawfully, leaflet, leaving, legislative, Levine, Louisiana, Lupin, matured, mercury, microinjection, Millennium, ml, MMV, monovalent, Mylan, Na, neglected, occasion, occurring, ofEloxatine, opening, OSRD, outperformed, pace, patentable, Patman, pecuniary, postpone, PrA, preemption, preservative, proceed, promoting, propensity, ProStrakan, Proteome, Province, psychological, PTS, PUMA, quater, rational, reaching, reaction, reassessing, recommend, recurrence, Reddy, reservation, resigned, revocation, Robinson, rotated, RP, session, severePlasmodium, shipment, signatory, statistically, sterile, Stiftung, subpoena, superiority, supplemented, suspend, Symbion, symptomatic, Synthon, Taiho, Takeda, tasked, temporarily, tendered, thecontinu, theoretical, thimerosal, traveler, trovax, unannounced, upholding, veralipride, verdict, VICP, Vinci, widest, Wisconsin
Filing tables
Filing exhibits
- 20-F Annual report (foreign)
- 1.1 Articles of Association (Statuts) of Sanofi (English Translation)
- 1.2 Board Charter (Reglement Interieur) of Sanofi (English Translation)
- 12.1 Certification by Christopher Viebacher, CEO, Required by Section 302
- 12.2 Certification by Jerome Contamine, Pfo, Required by Section 302
- 13.1 Certification by Christopher Viebacher, CEO Required by Section 906
- 13.2 Certification by Jerome Contamine, Pfo, Required by Section 906
- 23.1 Consent of Ernst & Young Audit
- 23.2 Consent of Pricewaterhousecoopers Audit
- 99.1 Report of the Chairman of the Board of Directors for 2011
SNY similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statements (Form S-8 Nos. 333-165418, 333-157685, 333-149203, 333-145074, 333-139555, 333-125490, 333-121584, 333-121583, 333-107238 and Form F-3 No. 333-165472) of Sanofi, of our reports dated March 5, 2012, with respect to the consolidated financial statements of Sanofi and its subsidiaries and the effectiveness of internal control over financial reporting of Sanofi and its subsidiaries, included in this Annual Report (Form 20-F) for the year ended December 31, 2011.
Ernst & Young Audit
Represented by Christian Chiarasini and Jacques Pierres
Christian Chiarasini | Jacques Pierres |
Paris-La Défense, France
March 5, 2012